Product Launches
Cloud-Clone Releases Allergy Research Toolbox Spanning ELISA Kits to Animal Models
By News Desk ·
Key takeaways
- Cloud-Clone's allergy portfolio covers six modules, from ELISA kits for IgE and Th2 cytokines to SPF-facility animal-model services.
- The reagents are validated for human, mouse, rat, rabbit and guinea-pig samples, with assays run on serum, plasma, tissue homogenate and bronchoalveolar-lavage fluid.
- Cloud-Clone's reagents and services have been cited across multiple international peer-reviewed journals, with references posted on its corporate website.
Cloud-Clone Corp. has launched a portfolio of reagents and pre-clinical services for allergic rhinitis research, aimed at type-2 airway inflammatory disorders. The company announced the offering on November 17, 2026, according to EIN Presswire. The portfolio spans ELISA kits, multiplex assays, recombinant proteins, antibodies, animal-model services and contract testing.
Inside Cloud-Clone's Six-Module Allergy Toolbox
The Cloud-Clone portfolio is organized into six modules, all compatible with human, mouse, rat, rabbit and guinea-pig samples. ELISA kits quantify IgE, the Th2 cytokines IL-4, IL-5 and IL-13, the alarmins TSLP, IL-33 and IL-25, plus IFN-γ, IL-31, IL-17 and IL-10, in serum, plasma, tissue homogenate and bronchoalveolar-lavage fluid. Multiplex assays on Luminex and CBA platforms measure several cytokines at once from limited sample volumes, which the company positions for longitudinal animal studies and high-throughput drug screening.
Recombinant proteins including IL-4, IL-33 and TSLP support in-vitro cellular stimulation and assay-standard preparation, and custom production is available for non-stock targets. Monoclonal and polyclonal antibodies are validated for western blot, immunohistochemistry and immunofluorescence, with custom generation and labelling offered. Animal-model and in-vivo services run in an SPF facility with customizable endpoints and pathological evaluation, and contract testing covers outsourced biochemical and cellular assays with full experimental reports.
The company said assay antibodies and recombinant proteins are produced in-house, which it says minimizes inter-batch inconsistency that arises when supplies come from multiple vendors. Cloud-Clone describes a typical workflow in which investigators commission an ovalbumin-sensitized allergic-rhinitis model, confirm it through behavioural scoring of sneezing and nasal scratching, then quantify serum IgE, IL-4 and IFN-γ by ELISA or multiplex panels. Post-intervention measurement of TSLP, IL-33, IL-25, IL-5 and IL-13 is used to distinguish whether compounds act on alarmin signalling or downstream effector cytokines. Rats are described as convenient for intranasal-challenge operations, while BALB/c mice are preferred for genetic and mechanistic studies.
Cloud-Clone's Assay and Antibody Records
Cloud-Clone launched a flow cytometry-based multiplex immunoassay platform with magnetic bead technology and more than 7,000 validated antibody pairs in February 2026, cutting detection time from about three days to about two hours, according to akta.pro company records. The same records list a proprietary antibody library exceeding 27,000 validated targets and note that Cloud-Clone ELISA kits have served as core measurement tools in publications in Cell, Nature Medicine and Nature Communications.
Earlier Cloud-Clone Assay Launches
Cloud-Clone released a competitive-ELISA kit for dihydrotestosterone targeting human, mouse and rat samples in October 2026, EIN Presswire reported, aiming to reduce cross-reactivity and batch variation in androgen research. The same month, EIN Presswire reported bead-based multiplex kits that measure up to 100 protein targets from 25 microliters of sample. In October 2026, EIN Presswire also reported validated antibodies for 97 targets across the Hippo, TGF-β/BMP and WNT pathways.